Start Date
Immediate
Expiry Date
31 Oct, 25
Salary
80000.0
Posted On
01 Aug, 25
Experience
0 year(s) or above
Remote Job
Yes
Telecommute
Yes
Sponsor Visa
No
Skills
Microbiology, Structural Biology
Industry
Hospital/Health Care
REQUIREMENTS:
Motivated individuals (PhD or MD) with a background in mass spectrometry-based proteomics, microbiology, structural biology (such as cryo-EM), and cancer immunology (ideally with animal model experience) are particularly welcome to . Interested candidates may submit their CV, including names and contact information for two-three references, a short description of their research experience, and goals to Yi Shi at (yi.shi@mssm.edu).
Responsibilities
.
Qualifications
.
Employer Description
Multiple postdoctoral positions are immediately available in Shi laboratory of Proteomics, Center for Protein Engineering and Therapeutics at Icahn School of Medicine at Mount Sinai in NYC
The lab is interested in developing biotechnologies for the analysis of biomolecules and macromolecular assemblies, with a focus on mass spectrometry/proteomic techniques. Recently, inspired by the high translational potential of the camelid single-chain antibodies (so called nanobodies), our lab has developed robust pipeline technologies and tools to facilitate nanobody drug discovery and therapeutic applications. The lab is also interested in the development and application of integrative structural approaches to study protein-protein and antibody-protein interactions. An emerging direction of the lab is to conjugate machine learning, structural biology and proteomic approaches to facilitate engineering and design towards novel protein therapeutics and vaccine development. The lab is vibrant, fun, and collaborative and support creative ideas and career development.
References:
Kim, S.J., et al (2018). Integrative structure and functional anatomy of a nuclear pore complex. Nature.
Xiang, Y., et al (2020). Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science.
Nambulli., et al (2021). Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Science Advances.
Xiang, Y., et al (2021). Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies. Cell Systems.
Sun, et al. (2021). Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes. Nature Communications.
Shen et al. (2021). A resource of high-quality nanobodies for drug delivery. iScience.
Sang, et al. (2021) Llamanade: an open-source computational pipeline for robust nanobody humanization. Structure.
Xiang et al (2022). Super-immunity by broadly protective nanobodies to sarbecoviruses. BioRxiv.
The lab is funded by multiple grants including the NIH, AAZ and MJFF. Competitive salaries can be provided for successful candidates.
Visit our lab at: https://www.shi-lab.org/.
Some related news are list here: